千亿体育

醫(yi)(yi)學(xue)(xue)(xue)部(bu)(bu)(bu)坐(zuo)倚珞(luo)珈山,環繞東湖(hu)水,綠樹成(cheng)蔭(yin),花香流溢。學(xue)(xue)(xue)部(bu)(bu)(bu)源于1943年成(cheng)立的湖(hu)北省省立醫(yi)(yi)學(xue)(xue)(xue)院(yuan),現在是武漢大學(xue)(xue)(xue)六大學(xue)(xue)(xue)部(bu)(bu)(bu)之一。 學(xue)(xue)(xue)部(bu)(bu)(bu)含基礎醫(yi)(yi)學(xue)(xue)(xue)院(yuan)、第一臨(lin)床學(xue)(xue)(xue)院(yuan)、第二(er)臨(lin)床學(xue)(xue)(xue)院(yuan)、口腔醫(yi)(yi)學(xue)(xue)(xue)院(yuan)、藥(yao)學(xue)(xue)(xue)院(yuan)、健康學(xue)(xue)(xue)院(yuan)、職業(ye)技術(shu)學(xue)(xue)(xue)院(yuan)...

地址: 湖北省武漢市武昌區東湖路115號
電話: 027-68759364
中國科學院院士: 鄧子新舒紅兵
國家級教學名師: 樊(fan)明(ming)文邊專
國家杰出青年基金獲得者: 鄧子新舒紅兵章曉聯李紅良卿國良
百千萬人才工程選者: 舒紅兵(bing)、黃從新章曉(xiao)聯?
萬人計劃: 領軍人(ren)才: 舒紅(hong)兵唐其柱李紅良(liang) ? ? ?
教育部新世紀優秀人才: 章曉聯、何小華樂江、 于紅剛 李雁鄭芳、
胡錦躍、 黃鶴(he)、李紅良、 張(zhang) 旗、 葉曉茜、 尚政(zheng)軍、 郭繼華(hua)、 張玉(yu)峰、
周海兵、 劉天(tian)罡、 王連榮、 瞿旭東、洪 葵

undefined

姓名: 李紅良

單位: 武漢大學基礎醫學院

職稱: 院長、教授、博導

郵箱: lihl@habitsandgoals.com

聯系電話: 027-68759302

研究方向:

1.心(xin)血(xue)管代謝性(xing)疾病的(de)發(fa)生(sheng)機制(zhi)與防治;研究免(mian)疫(yi)機制(zhi)、信號傳(chuan)導通路在心(xin)血(xue)管代謝性(xing)疾病發(fa)生(sheng)發(fa)展中的(de)作用及其機制(zhi)。

2.生物醫學(xue)工(gong)程: 基(ji)(ji)因敲除及轉基(ji)(ji)因動(dong)物模型的構建。

 








代表性論著:

1.Zhao GN, Zhang P, Gong J, Zhang XJ, Wang PX, Jiang Z, Shen LJ, Ji YX, Tong JJ, Wang YT, Wei QF, Wang Y, Zhu XY, Zhang X, Fang J, She ZG, Wang ZH, Huang Z, Li H*, TMBIM1 protects against nonalcoholic steatohepatitis in mice and monkeys by targeting TLR4 for lysosomal degradation, Nat Med., 2017 ;23(6):742-752.

2.Wang PX, Ji YX, Zhang XJ, Zhao LP, Yan ZZ, Zhang P, Shen LJ, Yang X, Fang J, Tian S, Zhu XY, Gong J, Zhang X, Wei QF, Wang Y, Li J, Wan L, Xie QG, She ZG, Wang ZH, Huang Z, Li H*, Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, Nat Med.2017;23(4):439-449.

3.Wang ZH, Zhang XJ, Zhang P, Wang XH, Chen I, Gao C, Deng KQ, Gong J, Yokota T, Wang H, Cass A, Ren SX, Vondriska T, Li GP, Yang HT, Xiao XS, Li H*, Wang Y*, A long non- coding RNA defines an epigenetic check point for cardiac hypertrophy. Nat Med. 2016 ,22(10):1131-1139.

4.Wang P, Zhang X, Luo P, Jiang X, Zhang P, Guo J, Zhao G, Zhu X, Zhang Y, Yang S and Li H*. Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. Nat Commun. 2016; 7: 10592.

5.Ji Y, Zhang P, Zhang X, Zhao Y, Deng K, Jiang X, Wang P, Huang Z and Li H*. The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling. Nat Commun. 2016; 7: 11267.

6.Deng K, Wang A, Ji Y, Zhang X, Fang J, Zhang Y, Zhang P, Jiang X, Gao L, Zhu X, Zhao Y, Gao L, Yang Q, Zhu X, Wei X, Pu J and Li H*. Suppressor of IKK? is an essential negative regulator of pathological cardiac hypertrophy. Nat Commun. 2016; 7: 11432.

7.Zhang S, Zhu L, Chen H, Zhang R, Zhang P, Jiang D, Gao L, Tian S, Wang L, Zhang Y, Wang P, Zhang X, Zhang X, Liu D and Li H*. Interferon regulatory factor 9 is critical for neointima formation following vascular injury. Nat Commun. 2014; 5: 5160.

8.Jiang D, Wei X, Zhang X, Liu Y, Zhang Y, Chen K, Gao L, Zhou H, Zhu X, Liu PP, Bond Lau W, Ma X, Zou Y, Zhang X, Fan G and Li H*. IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurinsignalling. Nat Commun. 2014; 5: 3303.

9.Lu Y, Li Z, Jiang D, Wang L, Zhang Y, Chen K, Zhang X, Liu Y, Fan G, Chen Y, Yang Q, Zhou Y, Zhang X, Liu D and Li H*. TRAF1 is a critical regulator of cerebral ischaemia–reperfusion injury and neuronal death. Nat Commun. 2013; 4: 2852.

10.Xiang M, Wang P, Wang A, Zhang X, Zhang Y, Zhang P, Mei F, Chen M and Li H*. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis. J Hepatol. 2016; 64: 1365-1377.

11.Hu J, Zhu X, Zhang X, Wang P, Zhang R, Zhang P, Zhao G, Gao L, Zhang X, Tian S and Li H*. Targeting TRAF3 signaling protects against hepatic ischemia/reperfusions injury. J Hepatol. 2016; 64: 146-159.

12.Gao L, Wang P, Zhang Y, Yu C, Ji Y, Wang X, Zhang P, Jiang X, Jin H, Huang Z, Zhang Z and Li H*. Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis. J Hepatol. 2016;65:125-36.

13.Wang P, Zhang R, Huang L, Zhu L, Jiang D, Chen H, Zhang Y, Tian S, Zhang X, Zhang X, Liu D and Li H*. Interferon regulatory factor 9 is a key mediator of hepatic ischemia/reperfusion injury. J Hepatol. 2015; 62: 111-120.

14.Zhu L, Wang A, Luo P, Wang X, Jiang D, Deng W, Zhang X, Wang T, Liu Y, Gao L, Zhang S, Zhang X, Zhang J and Li H*. Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice. J Hepatol. 2014; 60: 1046-1054.

15.Yan FJ, Zhang XJ, Wang WX, Ji YX, Wang PX, Yang Y, Gong J, Shen LJ, Zhu XY, Huang Z, Li H*. The E3 ligase TRIM8 targets TAK1 to promote insulin resistance and steatohepatitis. Hepatology. 2017;65(5):1492-1511.

16.Wang X, Zhang R, She Z, Zhang X, Jiang D, Wang T, Gao L, Deng W, Zhang S, Zhu L, Guo S, Chen K, Zhang X, Liu D and Li H*. Interferon regulatory factor 3 constrains IKKβ/NF-κB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology. 2014; 59: 870-885.

17.Zhang Y, Zhang XJ, Wang PX, Zhang P, Li H*.Reprogramming Innate Immune Signaling in Cardiometabolic Disease. Hypertension. 2017;69(5):747-760.

18.Zhu X, Fang J, Gong J, Guo J, Zhao G, Ji Y, Liu H, Wei X and Li H*. Cardiac-Specific EPI64C Blunts Pressure Overload–Induced Cardiac HypertrophyNovelty and Significance. Hypertension. 2016; 67: 866-877.

19.Gong J, Li Z, Guo S, Zhang X, Zhang P, Zhao G, Gao L, Zhang Y, Zheng A, Zhang X, Xiang M and Li H*. Neuron-Specific Tumor Necrosis Factor Receptor–Associated Factor 3 Is a Central Regulator of Neuronal Death in Acute Ischemic Stroke Hypertension. 2015; 66: 604-616.

20.Zhang X, Zhang P and Li H*. Interferon Regulatory Factor Signalings in Cardiometabolic Diseases. Hypertension. 2015; 66: 222-247.


友情鏈接
千亿体育